Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope
about
Antigen-specific immunotherapy of cervical and ovarian cancerStructural Engineering of pMHC Reagents for T Cell Vaccines and DiagnosticsAn enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.DNA vaccines for cervical cancerEngineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens.Activation of Akt as a mechanism for tumor immune evasion.Therapeutic HPV DNA vaccines.Perspectives for preventive and therapeutic HPV vaccines.Immunotherapy for cervical cancer: Research status and clinical potentialProperties and applications of single-chain major histocompatibility complex class I molecules.DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potencyDNA vaccines for cervical cancer: from bench to bedside.Single chain MHC I trimer-based DNA vaccines for protection against Listeria monocytogenes infectionIntranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protectionIntradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency.Nanog signaling in cancer promotes stem-like phenotype and immune evasionTargeted treatments for cervical cancer: a review.Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptidesSingle-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection.Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.Identification of HLA-A24-restricted CD8(+) cytotoxic T-cell epitopes derived from mammaglobin-A, a human breast cancer-associated antigenActivation and detection of HTLV-I Tax-specific CTLs by epitope expressing single-chain trimers of MHC class I in a rat modelNew Approaches to Immunotherapy for HPV Associated Cancers.Cancer genome sequencing and its implications for personalized cancer vaccines.Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.Therapeutic vaccines against human papillomavirus and cervical cancer.Basic and translational applications of engineered MHC class I proteins.Potential targets for pancreatic cancer immunotherapeutics.The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence.Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes.A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer.Adenovirus-mediated gene transfer of interleukin-23 shows prophylactic but not therapeutic antitumor effects.Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis.Introduction of a point mutation into an HLA class I single-chain trimer induces enhancement of CTL priming and antitumor immunity.Two novel HLA-A*0201 T-cell epitopes in avian H5N1 viral nucleoprotein induced specific immune responses in HHD mice.Hepatitis B virus core antigen epitopes presented by HLA-A2 single-chain trimers induce functional epitope-specific CD8+ T-cell responses in HLA-A2.1/Kb transgenic mice.Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.Therapeutic human papillomavirus vaccines: current clinical trials and future directions
P2860
Q27488697-3FD512F5-B8FF-471F-986D-E31F91D83B5EQ27647545-C3565DBB-0574-47F7-B605-EDAB25E9158FQ31121276-983242AE-640F-4A86-AEAF-C7369C57A7EFQ33680693-B13E261B-4DC5-4020-A324-30B9A6772C45Q33698112-A3E1B8DB-E352-4BDB-9A64-C41E0EBFB2B9Q33713327-9AC1BBD8-D974-48BE-888A-0A9428A44DFFQ33936427-500F77B4-9E71-42ED-95ED-D37F12D8A056Q34011494-286E9991-2D2A-467D-9EAC-1C61C44C122DQ34033763-EB2C63A4-1C9A-41B2-A5C6-A10CDEB5748CQ35075017-487000AD-449A-47F3-B59A-B80EB0615624Q35210348-ADD2F6C5-6753-4149-899E-8D975AB27F2CQ35234992-50F460B9-4CA3-47F0-B387-F1B9356AE782Q35785988-1137C185-587C-4C1F-A659-B06A394549A8Q36095558-9D8FC2B7-9046-4743-B83D-5AAB5D47F5B9Q36248706-F2D04B30-052C-4A85-9ADE-340EB003AF75Q36357895-1E6DB4C7-E2DF-4AB0-B06C-88FB3FE9A886Q36384032-9EC40343-9B8A-4B2E-8411-128C19075F83Q36512035-27A1610A-3ADC-4AAA-AF85-0980CBC5CF25Q36773225-C49B7D57-67BF-4F88-887A-4D23DB2EC3B8Q36780146-951B5CA8-49F3-4B33-8EAE-9226069A1C07Q36907752-C4B5EA16-D9E3-4034-98C1-F367EB165B1CQ36964053-43E98DC7-17B7-4F43-9660-89380FCCC195Q37137430-0E1ABFB3-CC87-4BF5-A424-08418CBF0531Q37148184-74431826-61E4-4F89-85CD-0A3F858E7B6EQ37374278-210081A4-0143-4F5E-A047-EE62EA7E0572Q37418916-FA2489E5-20D2-44C8-B42D-E22024DA4A2DQ37787436-6DCF599C-A5CB-45C6-8719-DA407A63B0B6Q37861220-6E4DC8CE-DB09-43DF-AAA5-0F47B60522BCQ38206518-CC16BE8A-B6C1-4478-BC3E-9BEDF8058FC1Q38804301-054D18D9-429B-45E3-9CBA-94E380CB8C3EQ39068550-6F222E79-17B3-4E47-8C4D-BCCE2F376EE6Q39965317-549B71E3-EB98-4406-8C8F-8FF7EB3EEDA3Q40447695-420072CD-D484-4F71-8EAE-BC83683E435AQ40898202-6AEF9648-739D-492D-B6AE-0B52D9637E7EQ42261256-AD09C9D3-44F5-4E0A-B428-FE486B52B184Q42831741-8900F76B-283D-4B56-B0A1-5F964BEF08E4Q50115667-13692128-7A65-4226-ADA1-F3BB895EA4FFQ56937332-106A7268-DE1C-426D-8AE1-0833586AE73F
P2860
Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Cancer immunotherapy using a D ...... E6 immunodominant CTL epitope
@ast
Cancer immunotherapy using a D ...... E6 immunodominant CTL epitope
@en
type
label
Cancer immunotherapy using a D ...... E6 immunodominant CTL epitope
@ast
Cancer immunotherapy using a D ...... E6 immunodominant CTL epitope
@en
prefLabel
Cancer immunotherapy using a D ...... E6 immunodominant CTL epitope
@ast
Cancer immunotherapy using a D ...... E6 immunodominant CTL epitope
@en
P2093
P2860
P356
P1433
P1476
Cancer immunotherapy using a D ...... E6 immunodominant CTL epitope
@en
P2093
D A K Boyd
T H Hansen
P2860
P2888
P304
P356
10.1038/SJ.GT.3302519
P577
2005-08-01T00:00:00Z